Cargando…

Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat

The application of erythropoietin (EPO) can bring about a rare but serious complication called anti‐EPO antibody‐mediated pure red cell aplasia (PRCA). Once the disease is diagnosed, EPO administration should be stopped immediately. However, after the removal of the anti‐EPO antibody, treating anaem...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yunzhou, Cai, Xudong, Ni, Jianing, Lin, Xiaomeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754494/
https://www.ncbi.nlm.nih.gov/pubmed/32856389
http://dx.doi.org/10.1111/ijlh.13325
_version_ 1783626208518340608
author Wu, Yunzhou
Cai, Xudong
Ni, Jianing
Lin, Xiaomeng
author_facet Wu, Yunzhou
Cai, Xudong
Ni, Jianing
Lin, Xiaomeng
author_sort Wu, Yunzhou
collection PubMed
description The application of erythropoietin (EPO) can bring about a rare but serious complication called anti‐EPO antibody‐mediated pure red cell aplasia (PRCA). Once the disease is diagnosed, EPO administration should be stopped immediately. However, after the removal of the anti‐EPO antibody, treating anaemia in these patients with chronic renal disease with EPO therapy is difficult, as restarting EPO therapy risks the recurrence of anti‐EPO antibody‐mediated PRCA. A 26‐year‐old man with anaemia related to renal failure, who was administered recombinant human EPO subcutaneously, developed anti‐EPO antibody‐mediated PRCA. After removal of antibodies by treatment with corticosteroids and cyclosporine, therapy for anaemia of chronic renal disease with roxadustat achieved good results. Roxadustat is a new type of drug for the treatment of anaemia, and it can stimulate endogenous EPO within or near the physiologic range and increase haemoglobin levels.
format Online
Article
Text
id pubmed-7754494
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77544942020-12-28 Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat Wu, Yunzhou Cai, Xudong Ni, Jianing Lin, Xiaomeng Int J Lab Hematol Letter to the Editors The application of erythropoietin (EPO) can bring about a rare but serious complication called anti‐EPO antibody‐mediated pure red cell aplasia (PRCA). Once the disease is diagnosed, EPO administration should be stopped immediately. However, after the removal of the anti‐EPO antibody, treating anaemia in these patients with chronic renal disease with EPO therapy is difficult, as restarting EPO therapy risks the recurrence of anti‐EPO antibody‐mediated PRCA. A 26‐year‐old man with anaemia related to renal failure, who was administered recombinant human EPO subcutaneously, developed anti‐EPO antibody‐mediated PRCA. After removal of antibodies by treatment with corticosteroids and cyclosporine, therapy for anaemia of chronic renal disease with roxadustat achieved good results. Roxadustat is a new type of drug for the treatment of anaemia, and it can stimulate endogenous EPO within or near the physiologic range and increase haemoglobin levels. John Wiley and Sons Inc. 2020-08-27 2020-12 /pmc/articles/PMC7754494/ /pubmed/32856389 http://dx.doi.org/10.1111/ijlh.13325 Text en © 2020 The Authors. International Journal of Laboratory Hematology published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editors
Wu, Yunzhou
Cai, Xudong
Ni, Jianing
Lin, Xiaomeng
Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
title Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
title_full Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
title_fullStr Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
title_full_unstemmed Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
title_short Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
title_sort resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
topic Letter to the Editors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754494/
https://www.ncbi.nlm.nih.gov/pubmed/32856389
http://dx.doi.org/10.1111/ijlh.13325
work_keys_str_mv AT wuyunzhou resolutionofepoetininducedpureredcellaplasiasuccessfulrechallengewithroxadustat
AT caixudong resolutionofepoetininducedpureredcellaplasiasuccessfulrechallengewithroxadustat
AT nijianing resolutionofepoetininducedpureredcellaplasiasuccessfulrechallengewithroxadustat
AT linxiaomeng resolutionofepoetininducedpureredcellaplasiasuccessfulrechallengewithroxadustat